905-based Prollenium Medical Technologies
has announced that it will again report strong year-over-year revenue and profit growth this year, after seeing 524 per cent revenue growth over the past five years. The pace of its growth has seen it ranked on PROFIT magazines list of the fastest-growing companies in Canada for four years running.
And it's growth plans appear to continue apace: in May, the company announced that it had been cleared to distribute it's Revanesse Dermal Fillers, bringing to 60 the number of countries in which the company's products are distributed. In addition, the company says it has recently completed a double-blind study that will lead to entry into the large US market.
Over the phone, a company employee says that plans are afoot to move the company into larger offices to accommodate expansion, and that the company will soon be launching a line of injectable pain relievers for sufferers of osteoarthritis. Other aesthetics products are in the company's pipeline.
Company VP Khasha Ighanian says the company is in the process of "leveraging the efforts of our strong R&D team with our ability to bring new products to market quickly," and that he is "optimistic about the next five years."
Writer: Edward Keenan
Source: Khasha Ighanian, VP, Prollenium Medical Technologies
Got an Innovation & Job News tip? Email [email protected].